Clinical and Adverse Outcomes Associated With Concomitant Use of CYP2D6-Metabolized Opioids With Antidepressants in Older Nursing Home Residents : A Target Trial Emulation Study.

ABSTRACT:

Background

Limited evidence exists on the safety of pharmacokinetic interactions of cytochrome P450 (CYP) 2D6 (CYP2D6)-metabolized opioids with antidepressants among older nursing home (NH) residents.

Objective

To investigate the associations of concomitant use of CYP2D6-metabolized opioids and antidepressants with clinical outcomes and opioid-related adverse events (ORAEs).

Design

Retrospective cohort study using a target trial emulation framework.

Setting

100% Medicare NH sample linked to Minimum Data Set (MDS) from 2010 to 2021.

Participants

Long-term residents aged 65 years and older receiving CYP2D6-metabolized opioids with a disease indication for antidepressant use.

Intervention

Initiating CYP2D6-inhibiting versus CYP2D6-neutral antidepress

SUBMITTER: Wei YJ 

PROVIDER: S-EPMC11929157 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature